Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06045585

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Sponsor: Guangdong Second Provincial General Hospital

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions infusion of JY231 injection

Updated 4 times since 2023 Last updated: Sep 17, 2023 Started: Aug 18, 2023 Primary completion: Aug 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Relapsed or Refractory B-cell Lymphoma and is currently ongoing. Guangdong Second Provincial General Hospital leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown EARLY_PHASE1

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Oct 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Second Provincial General Hospital

Data source: Guangdong Second Provincial General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China